Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABOS OTCMKTS:LTUS NASDAQ:PYXS NYSE:VNRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$1.38+5.3%$1.14$0.86▼$3.60$79.35M0.11293,288 shs412,186 shsLTUSLotus Pharmaceuticals$0.01+15.1%$0.01$0.00▼$0.01$26.18M-2.4849,705 shs12,883 shsPYXSPyxis Oncology$1.19+2.6%$1.19$0.83▼$5.39$71.86M1.13721,455 shs388,927 shsVNRXVolitionRx$0.70+8.4%$0.62$0.40▼$0.94$67.17M1.2206,805 shs220,699 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals+5.34%+10.40%+21.05%+53.20%-56.19%LTUSLotus Pharmaceuticals0.00%-10.81%+70.69%+57.14%+1,550.00%PYXSPyxis Oncology+2.59%+1.71%-1.65%+23.53%-66.57%VNRXVolitionRx+7.05%+5.90%-2.11%+42.86%+8.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABOSAcumen Pharmaceuticals2.8503 of 5 stars3.54.00.00.01.91.70.6LTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APYXSPyxis Oncology2.3814 of 5 stars3.43.00.00.02.60.80.6VNRXVolitionRx2.1012 of 5 stars3.50.00.00.02.22.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABOSAcumen Pharmaceuticals 3.00Buy$6.33358.94% UpsideLTUSLotus Pharmaceuticals 0.00N/AN/AN/APYXSPyxis Oncology 2.80Moderate Buy$9.00656.30% UpsideVNRXVolitionRx 3.00Buy$3.50400.00% UpsideCurrent Analyst Ratings BreakdownLatest LTUS, PYXS, ABOS, and VNRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.006/17/2025ABOSAcumen PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$4.006/10/2025VNRXVolitionRxJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$3.005/19/2025PYXSPyxis OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/30/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABOSAcumen PharmaceuticalsN/AN/AN/AN/A$3.03 per shareN/ALTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AN/APYXSPyxis Oncology$16.15M4.56N/AN/A$2.03 per share0.59VNRXVolitionRx$1.31M55.63N/AN/A($0.11) per share-6.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABOSAcumen Pharmaceuticals-$102.33M-$1.94N/AN/AN/AN/A-58.24%-46.53%8/12/2025 (Estimated)LTUSLotus Pharmaceuticals$110KN/A0.00∞N/AN/AN/AN/AN/APYXSPyxis Oncology-$77.33M-$1.59N/AN/AN/AN/A-57.49%-45.17%8/13/2025 (Estimated)VNRXVolitionRx-$35.32M-$0.27N/A∞N/A-2,321.14%N/A-163.39%N/ALatest LTUS, PYXS, ABOS, and VNRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025PYXSPyxis Oncology-$0.36N/AN/AN/AN/AN/A8/12/2025Q2 2025ABOSAcumen Pharmaceuticals-$0.54N/AN/AN/AN/AN/A5/15/2025Q1 2025PYXSPyxis Oncology-$0.29-$0.35-$0.06-$0.35N/AN/A5/13/2025Q1 2025ABOSAcumen Pharmaceuticals-$0.56-$0.48+$0.08-$0.48N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABOSAcumen PharmaceuticalsN/AN/AN/AN/AN/ALTUSLotus PharmaceuticalsN/AN/AN/AN/AN/APYXSPyxis OncologyN/AN/AN/AN/AN/AVNRXVolitionRxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABOSAcumen Pharmaceuticals0.198.028.02LTUSLotus PharmaceuticalsN/AN/AN/APYXSPyxis OncologyN/A7.757.75VNRXVolitionRxN/A0.220.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABOSAcumen Pharmaceuticals71.01%LTUSLotus PharmaceuticalsN/APYXSPyxis Oncology39.09%VNRXVolitionRx8.09%Insider OwnershipCompanyInsider OwnershipABOSAcumen Pharmaceuticals9.30%LTUSLotus PharmaceuticalsN/APYXSPyxis Oncology10.60%VNRXVolitionRx10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABOSAcumen Pharmaceuticals2060.57 million54.94 millionOptionableLTUSLotus Pharmaceuticals2302.64 billionN/ANot OptionablePYXSPyxis Oncology6061.95 million55.38 millionOptionableVNRXVolitionRx80103.98 million80.80 millionOptionableLTUS, PYXS, ABOS, and VNRX HeadlinesRecent News About These CompaniesNu.Q® Discover Expands Global Adoption and Epigenetic InnovationJuly 16 at 8:00 AM | prnewswire.comVolitionRx (NYSE:VNRX) Earns Buy Rating from D. Boral CapitalJuly 12, 2025 | americanbankingnews.comVolitionRx Limited (VNRX) - Yahoo FinanceJuly 11, 2025 | nz.finance.yahoo.comVolitionRx (NYSE:VNRX) Given "Buy" Rating at D. Boral CapitalJuly 9, 2025 | marketbeat.comVolition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of NucleosomesJuly 8, 2025 | prnewswire.comVolition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ FailureJune 12, 2025 | prnewswire.comJones Trading Initiates Coverage of VolitionRx (VNRX) with Buy RecommendationJune 11, 2025 | msn.comVolitionRx director Guy Innes buys $10,772 in common stockJune 5, 2025 | investing.comInsider Buying: VolitionRx Limited (NYSE:VNRX) Director Buys 20,000 Shares of StockJune 5, 2025 | insidertrades.comVolition Announces Two Oral Presentations at Asian Meeting of Animal Medicine SpecialtiesJune 4, 2025 | prnewswire.comVolitionRX shares hold as Benchmark maintains ratingMay 21, 2025 | uk.investing.comVolitionRx Limited (AMEX:VNRX) Q1 2025 Earnings Call TranscriptMay 20, 2025 | msn.comInsider Buying: VolitionRx Limited (NYSE:VNRX) Insider Acquires 50,000 Shares of StockMay 20, 2025 | insidertrades.comVolitionRx Limited Announces Successful Detection of Nucleosomes in CatsMay 19, 2025 | prnewswire.comVolitionRX aims for cash flow neutrality in 2025 as human diagnostics licensing advancesMay 16, 2025 | msn.comVolitionRX Limited (VNRX) Q1 2025 Earnings Call TranscriptMay 16, 2025 | seekingalpha.comVolitionRx Limited Announces First Quarter 2025 Financial Results and Business UpdateMay 15, 2025 | prnewswire.comVolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business UpdateMay 12, 2025 | prnewswire.comVolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoptionMay 7, 2025 | prnewswire.comVolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar marketsApril 29, 2025 | prnewswire.comVolitionRx enters new sales agreement, terminates old oneApril 24, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLTUS, PYXS, ABOS, and VNRX Company DescriptionsAcumen Pharmaceuticals NASDAQ:ABOS$1.38 +0.07 (+5.34%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$1.39 +0.01 (+0.72%) As of 07:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Lotus Pharmaceuticals OTCMKTS:LTUS$0.0099 +0.00 (+15.12%) As of 07/15/2025 12:19 PM EasternLotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee.Pyxis Oncology NASDAQ:PYXS$1.19 +0.03 (+2.59%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$1.18 -0.01 (-1.26%) As of 05:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.VolitionRx NYSE:VNRX$0.70 +0.05 (+8.36%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$0.70 +0.01 (+0.71%) As of 07:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
